Evaluating the impact of geriatric assessments on treatment for older AML patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the physiologic age of newly diagnosed acute myeloid leukemia (AML) patients aged 50 and older, focusing on a holistic evaluation rather than chronological age alone. By measuring various health parameters at baseline, the study will analyze outcomes such as treatment toxicity, early mortality, remission rates, and long-term survival in patients receiving either intensive or non-intensive treatment. The findings will help inform new guidelines for treating older adults with AML.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* AML diagnosis by peripheral flow cytometry and/or bone marrow aspirate and biopsy
* New diagnosis being considered for new line of treatment
* Age ≥ 50 years.
* Performance status 0,1, and 2

Exclusion Criteria:

* Inability to understand or unable to sign a written informed consent
* Unable to fill out questionnaires on their own and/or do not have someone to help complete them

Where it's running

• Abramson Cancer Center at University of Pennsylvania
  Philadelphia, Pennsylvania, United States Recruiting

Study contacts

• Principal investigator: Catherine Lai, MD — Abramson Cancer Center at Penn Medicine
• Study coordinator: Colleen Redlinger
• Email: colleen.redlinger@pennmedicine.upenn.edu
• Phone: 2152209693

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Quality-of-life–guided red blood cell transfusions for people with refractory MDS or AML

  We test whether using routine EQ-5D-5L quality-of-life scores to decide when to give red blood cell transfusions can safely reduce the number of transfusions for adults with refractory MDS or AML who are receiving only palliative care.

  Recruiting Centre Hospitalier Universitaire de Nice · Nice · NCT07328191

• Venetoclax plus Azacitidine versus Daunorubicin/Idarubicin plus Cytarabine induction for fit older adults with AML

  This trial will test whether Venetoclax plus Azacitidine works as well as standard daunorubicin or idarubicin plus cytarabine induction in fit adults aged 55–75 with acute myeloid leukemia.

  Recruiting Phase 3 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT07132684

• Post-remission treatments for MRD-positive adult AML

  This study will try different drug regimens to see if they help people aged 14 and older with AML who are in remission but still MRD-positive stay relapse-free and live longer.

  Recruiting Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07131059

• Venetoclax plus a short (3-day) decitabine schedule for untreated elderly or unfit adults with AML

  This trial will see if venetoclax combined with a short (3-day) decitabine course helps people with newly diagnosed AML who are elderly or cannot receive standard chemotherapy.

  Recruiting The Second Hospital of Hebei Medical University · Hebei · NCT07117422

• Observational study of older patients with acute myeloid leukemia receiving intensive treatment

  This study looks at older patients with acute myeloid leukemia to see how well intensive treatment works for them and what factors might affect their recovery and survival.

  Recruiting at 27 sites French Innovative Leukemia Organisation · Angers and 26 other locations · NCT06891144

• Using eganelisib alone and with cytarabine for treating relapsed/refractory AML

  This study is testing if a new drug called eganelisib, used alone or with another drug called cytarabine, can help people with relapsed or hard-to-treat acute myeloid leukemia feel better.

  Recruiting at 12 sites Phase 1 Stelexis BioSciences · Duarte, California and 11 other locations · NCT06533761

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.